The selection of varieties in the collection did not pass the "consistency evaluation", and the bidding pharmaceutical company was ordered to stop using

There are no reviews in the selection of varieties in the collection.

On July 13, Zhejiang Pharmaceutical Procurement Platform issued an announcement saying that due to the "non -consistency evaluation logo", the injection of cephalosporin sodium under the injection of the Guangdong Jinsheng Jindu Pharmaceutical Co., Ltd. Purchasing procurement agreement.

Jincheng Jincheng Pharmaceutical was established in 2015. It is a 51%subsidiary of Shandong Jincheng Pharmaceutical Holdings in A -share listed companies. It is also a cephalosporin "professional household". There are 42 cephalospatin pink pins.

In 2021, the company's injection of cephalosporin sodium and cephalosporin in the fifth batch of cephalosporins won the bid.

This time, sodium cephalosporin sodium by Zhejiang's injection is a three generations of cephalosporin. It can be used to treat pneumonia and lower respiratory tract infections. It is one of the most important products of Jincheng Jintou Pharmaceutical. This product passed the consistency evaluation in October 2021. Jincheng Jintou Pharmaceutical is one of the first criticism companies.

Being able to enter the collection of collecting bids means that the relevant information must have passed the review of Zhejiang Province before. Today, why is this product kicked out of the purchase list?

A staff member of Jincheng Jincheng Pharmaceutical told Jianxian Bureau: The product has indeed passed the consistency evaluation, and it is not clear why the agreement has been terminated.

There is a problem with the program, but the company has not been fined

On October 21, 2021, during the second batch of pharmaceutical collection of the provincial -level pharmaceutical collection in Zhejiang Province, the procurement regulations for sodium sodium for cephalosporin were injected, with a total procurement of 934,500, and the procurement cycle was 1 year.

In the application qualification, Zhejiang Province did not make provisions on the specific time limit of the product through consistency evaluation, but only required enterprises to complete the application work from October 22 to November 10 of that year.

According to the information disclosed by Zhejiang Province, during the implementation of the results of the selection, the actual products provided by Jincheng Jintou Pharmaceutical did not pass the logo of consistency evaluation and did not match the materials submitted at the time of registration.

The Jianzhi Bureau noticed that on the same day of the second batch of collection documents in Zhejiang Province, the State Drug Administration issued 4 batches of cephalosporin sodium to the injection of Jincheng Jincheng Pharmaceutical. A few days later, Jincheng Pharmaceutical announced that the subsidiary Jincheng Jincheng Pharmaceutical had received the approval of the State Drug Administration, and the sodium of cephalosporin was injected with the consistency evaluation of the quality and efficacy.

Judging from the results of the collection of collection, on October 21, on the day of the second batch of provincial collection of Zhejiang Province, Jincheng Jintou Pharmaceutical received was the "consistency evaluation logo" required by Zhejiang.

What happened to happen, the product rushed on the day when the collection was launched. Is this considered the collection requirements?

According to Zhejiang's processing results, such review documents do not meet the requirements.

According to the CPM new drug research and development monitoring database, at present, there are 21 different specifications of injection of cephalosporin sodium in 10 different specifications in China through consistency evaluation. Jincheng Jincheng Pharmaceutical is the first batch of overview, and the competition is very fierce.

In this case, morning marketing is the best way to seize the market.

According to the second batch of collection documents in Zhejiang Province, if the participating enterprises provide false certification documents and documents, or serious quality problems occur in the selected drugs, they may be included in the "illegal list" after investigation. However, the Zhejiang side did not implement strict punishment regulations on Jincheng Jinsin Pharmaceutical. It was just to terminate the procurement agreement and subsequent processing to the place:

"All medical institutions no longer need to complete the agreed purchase volume with Jincheng Jincheng Pharmaceutical in accordance with the purchase and marketing agreement. If the loss or other civil rights are infringed, the relevant institutions can defend their rights in accordance with the law."

In other words, this subsidiary of Jincheng Medicine may face a series of civil disputes from various hospitals.

Jacking or collection, rules or rules

Generally speaking, if the company's bidding enterprises have problems with product supply or clinical use for their own reasons, they will be included in the list of illegal or dishonesty and lose their opportunities to continue participating in the collection of drug collection.

In August 2021, the North China Pharmaceutical Break-release Capsule Capsule in Shandong was a typical case. It was canceled from August 11, 2021 to May 10, 2022 to participate in the national collection of national collection.

The Jianzhi Bureau noticed that before the North China Pharmaceutical Incident, the results of the dishonesty behavior of enterprises in various recruits were "revoking the hanging network" and "exit purchase platform". After the North China Pharmaceutical Incident, the wind was cranked for a while, and all places began to formulate corresponding specifications to increase the supervision of subsequent supply issues.

Take Gansu Province as an example. Previously, the Gansu Provincial Medical Insurance Bureau had requested that the selected enterprises in various episodes need to establish a distribution relationship covering 103 areas in the province. But as of the end of June this year, a large number of enterprises were still unfinished. To this end, Gansu Province has eligible to qualify for the relevant products of 12 companies, cancel the procurement agreement of 61 companies, and reduce the agreed purchase volume.

Special circumstances such as Jincheng Jincou Pharmaceutical have not occurred in various places before. Zhejiang also encountered such a situation in local collection and mining, so it would be allowed to defend their rights in various medical institutions without the provincial recruitment platform. Punishment at the level. However, the Zhejiang Provincial Recruitment Platform still emphasizes that all medical institutions still hope that all medical institutions will "choose carefully" and try to avoid purchasing medicines from companies that have default and dishonesty.

Zhejiang is stricter in various rules in local collection. In the second batch of provincial collection last year, Zhejiang specified that only companies with more than 2 times or more production capacity of annual production capacity were eligible for declaration.

Although the problem of Jincheng Jintou Pharmaceutical, although it has not risen to withdraw from the network or canceled the qualifications of collecting collection, it also knocked a alarm clock for peers: the collection cannot be shameless, and the problem is not small.### consistency evaluation logo ###

- END -